MOUNT KISCO, NY, USA, and TOKYO, Japan I April 25, 2013 I Perosphere Inc. and Daiichi Sankyo Company, Limited announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.
Daiichi Sankyo to support and co-sponsor phase 1 clinical study